Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 2, 2009Cancer ResearchOpen Access

The mRNA-Destabilizing Protein Tristetraprolin Is Suppressed in Many Cancers, Altering Tumorigenic Phenotypes and Patient Prognosis

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSarah E. BrennanYKYuki KuwanoNANadim W. Alkharouf

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Brennan et al. (2009) studied this question.

synapsesocial.com/papers/6ab0cb9c2ea84e464866d977https://doi.org/10.1158/0008-5472.can-08-4238
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AU-rich elements and associated factors: are there unifying principles?2005 · 1,063 citations
  2. 2AU-rich element-mediated translational control: complexity and multiple activities of <i>trans</i>-activating factors2002 · 215 citations
  3. 3Down-Regulation of Cyclin D1 Expression by Prostaglandin A <sub>2</sub> Is Mediated by Enhanced Cyclin D1 mRNA Turnover2000 · 134 citations
  4. 4Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma2004 · 152 citations
  5. 5Tristetraprolin Inhibits Ras-dependent Tumor Vascularization by Inducing Vascular Endothelial Growth Factor mRNA Degradation2007 · 99 citations